Durvalumab
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
July, 2024
July 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Jun
Durvalumab
Jul 26, 2024, 06:54 |
Insight
Discussions around updated OS data from Aegean Trial
Discussions around updated OS data from Aegean Trial Amol Akhade shared a post on X:…
Jul 11, 2024, 10:49 |
Insight
Alberto Hernando-Calvo: Durvalumab with Olaparib or Cediranib in patients with pMMR CRC or Pancreatic Cancer
Alberto Hernando-Calvo, Clinician scientist at Vall d'Hebron Barcelona Hospital, shared on X: "Phase II, open-label,…
Jul 8, 2024, 14:02 |
Insight
Real world outcomes with durvalumab after chemoradiation for stage III NSCLC in an elderly population
Stephen Liu, shared a post on X about a recent paper titled "Real-World Efficacy and…
Jul 6, 2024, 05:13 |
Insight
Tanja Obradovic: Choosing immunotherapy treatment for early resectable NSCLC
Tanja Obradovic shared on LinkedIn: "Choosing immunotherapy treatment options with PD(L)-1 inhibitors for early resectable non–small…
Jul 5, 2024, 02:47 |
Drugs
A new standard for treating limited-stage small cell lung cancer - Sarah Cannon Research Institute
Sarah Cannon Research Institute shared on LinkedIn: "Dr. David R. Spigel recently shared research on durvalumab…
Jun 28, 2024, 14:34 |
Blog
María Natalia Gandur Quiroga: Imfinzi Shows Significant Survival Benefits in NIAGARA Phase III Trial
María Natalia Gandur Quiroga shared on LinkedIn: . "Imfinzi Shows Significant Survival Benefits in NIAGARA…
Jun 27, 2024, 14:43 |
Insight
Amol Akhade: Landscape for urothelial carcinoma treatment is rapidly evolving
Amol Akhade shared on X: "The landscape for urothelial carcinoma treatment is rapidly evolving. Now…
Jun 26, 2024, 15:22 |
Insight
Results from the NIAGARA Phase III trial
AztraZeneca released the results of the NIAGARA phase III trial, where INFINZI (durvalumab) showed EFS…
Jun 26, 2024, 08:30 |
Insight
IMFINZI (durvalumab) showed improved EFS and OS for MIBC in NIAGARA Phase III trial
First immunotherapy regimen before and after surgery to extend survival in bladder cancer Positive high-level results…
Jun 17, 2024, 04:08 |
Insight
Sergio Cifuentes: Key Changes to My Oncology Practice from ASCO2024
Sergio Cifuentes, Cancer Research Project Manager at CENEIT México, shared a post on X: "My…
Jun 9, 2024, 01:38 |
Insight
Stephen V Liu reflects on OS from PACIFIC-R
Stephen V Liu shared the following insight on X: "OS from PACIFIC-R: real-world outcomes with…
Jun 6, 2024, 04:19 |
Opinion
Roy Herbst shared the updated results from the COAST clinical trial - Yale Cancer Center
Yale Cancer Center shared a post on X: "Roy Herbst shared the updated results from…
Jun 4, 2024, 14:59 |
Societies
15 Posts From ASCO24 Day 4 You Should Not Miss!
The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting is being held from May…
Jun 2, 2024, 22:20 |
Insight
Sylvester Cancer study on immunotherapy drug durvalumab shows limited access globally due to cost constraints
Access to Targeted Lung Cancer Drug Is Cost-Prohibitive Globally Many countries with national healthcare systems…
May 27, 2024, 04:19 |
Opinion
Gilberto Lopes: My top ASCO24 lung cancer abstracts!
Gilberto Lopes, Chief of the Division of Medical Oncology at Sylvester Comprehensive Cancer Center, shared…
May 23, 2024, 13:33 |
Insight
Tom Powles: Debate about activity of neoadjuvant vs adjuvant vs both is ongoing
Tom Powles, Director of Barts Cancer Center, shared a post on X: "Neoadjuvant chemo/nivolumab with…
May 19, 2024, 10:55 |
Insight
Dhruba Deb: The 8 SCLC projects Lung Cancer Research Foundation recently funded
Dhruba Deb, Senior Director of Research and Administration at Lung Cancer Research Foundation, shared on…
May 12, 2024, 07:27 |
Drugs
Tanja Obradovic summarizes the latest news on immunotherapy with chemoradiation NSCLC
Tanja Obradovic, Vice President of Oncology Scientific Affairs at ICON, shared on LinkedIn: “Based on what…
Apr 28, 2024, 11:04 |
Blog
Ana I. Velázquez Mañana: ASCO24 abstract titles are out! Exciting Plenary Session, specially for LCSM community
Ana I. Velázquez Mañana shared on X/Twitter: “ASCO24 abstract titles are out! Exciting Plenary Session, specially…
Apr 15, 2024, 02:52 |
Blog
Petros Grivas: Trial is open and we look for more sites!
Petros Grivas, GU oncologist at Fred Hutchinson Cancer Center and director of the University of…
Apr 8, 2024, 14:26 |
Insight
Shubh Goel: ADRIATIC Phase III trial for LS-SCLC couldn’t come at a more critical time for patients
Shubh Goel, VP and US Franchise Head, Immuno-Oncology and GI Tumors at AstraZeneca, shared a post…
Apr 6, 2024, 16:25 |
Insight
New Article Alert! FOLFIRI plus durvalumab with or without tremelimumab in advanced gastric or GEJ adenocarcinoma
FOLFIRI Plus Durvalumab With or Without Tremelimumab in Second-Line Treatment of Advanced Gastric or Gastroesophageal…
Apr 5, 2024, 08:29 |
Drugs
Piotr Wysocki: Promising activity of maintenance olaparib in advanced breast cancer patients responding to platinum-based chemotherapy
Piotr Wysocki, Professor of Medicine and Head of the Department of Oncology at Jagiellonian University…
Mar 28, 2024, 02:23 |
Drugs
Angela Lamarca: Great news for patients diagnosed with Biliary Malignancies and HCC in Spain
Angela Lamarca, Consultant in Medical Oncology at Jiménez Díaz Foundation University Hospital, shared a post…
Mar 25, 2024, 15:21 |
Insight
Gerry Hanna: Breaking from ELCC - PACIFIC-2 is negative
Gerry Hanna, Chair of the Division of Cancer and Specialist Medicine at Belfast Health and…
Mar 25, 2024, 15:15 |
Societies
25 Posts Not To Miss From ELCC 2024
The European Lung Cancer Congress (ELCC 2024) took place in Prague, Czech Republic, from 20th…
Feb 21, 2024, 18:13 |
Insight
Erman Akkus: Tremelimumab plus durvalumab (STRIDE) in HCC-HIMALAYA update
Erman Akkus, Medical Oncology Fellow at Ankara University, shared on X/Twitter: "Tremelimumab plus durvalumab (STRIDE)…
Feb 7, 2024, 12:46 |
Blog
Amin Nassar presents the results of a multicenter retrospective cohort for osimertinib and durvalumab in unresectable EGFR-mutant NSCLC
Amin Nassar, Hematology/Oncology Fellow at Yale University, shared a post on X/Twitter: "1. Pumped to…
Feb 5, 2024, 11:27 |
Insight
Stephen V Liu: The optimal strategy for unresectable stage III NSCLC after chemoradiation in EGFR mutant NSCLC
Stephen V Liu, Director of Thoracic Oncology and Developmental Therapeutics at Lombardi Comprehensive Cancer Center,…
Jan 26, 2024, 17:17 |
Societies
30 Posts Not To Miss From ASCO GI24
The ASCO Gastrointestinal Cancer Symposium (GI24) took place from the 18th to the 20th of…
Jul 19, 2023, 18:03 |
Drugs
Impact of TMB, PD-L1 , genomic features, and pneumonitis on CRT and durvalumab response in stage III NSCLC - João Alessi
Glad to share our paper recently published in Nature. In which, we report the impact…
Jun 12, 2023, 03:13 |
Drugs
The third country worldwide to approve this medication for HCC in combination with Durvalumab - Prof.Humaid Al-Shamsi
Last night in Dubai , in collaboration with AstraZeneca we successfully launched tremelimumab for the treatment of…
All:
32
Posts:
1 - 100
The largest philanthropic partnership in The V Foundation’s history - Dolphins Cancer Challenge
Glecirasib: A Promising Novel KRAS G12C Inhibitor in Clinical Development
How the Médecins Sans Frontières Journal Inspired a Lifetime of Humanitarian Service: Paul Spiegel
OncoDaily Party and Yvonne Award Photos - Part 1
Michael Douglas: The Untold Story of His Battle Against Cancer
Facebook
RSS Feed
Twitter
Linkedin
Youtube